News stories about Akorn (NASDAQ:AKRX) have been trending somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akorn earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 75 out of 100, meaning that recent news coverage is likely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- DR Horton Sees Unusually High Options Volume (NYSE:DHI) (ibusinesslines.com)
- Akorn, Inc. (AKRX) Analysts Remain Upbeat Despite -5.23% Loss – AllStockNews (allstocknews.com)
- ETFs with exposure to Akorn, Inc. : July 13, 2017 (finance.yahoo.com)
- Shares of AKRX Up 54.9% Since Uptrend Call on Shares (mysmartrend.com)
Akorn (NASDAQ AKRX) traded up 0.045% during midday trading on Friday, hitting $33.645. The company had a trading volume of 2,798,373 shares. The stock has a market cap of $4.19 billion, a price-to-earnings ratio of 22.966 and a beta of 1.36. The company’s 50 day moving average is $33.32 and its 200 day moving average is $26.53. Akorn has a 12-month low of $17.61 and a 12-month high of $35.40.
Several research firms have issued reports on AKRX. Royal Bank Of Canada set a $34.00 target price on Akorn and gave the stock a “hold” rating in a research report on Tuesday, June 27th. BidaskClub upgraded Akorn from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Zacks Investment Research upgraded Akorn from a “sell” rating to a “hold” rating in a research report on Monday, May 8th. TheStreet upgraded Akorn from a “c+” rating to a “b-” rating in a research report on Thursday, April 20th. Finally, Gabelli reiterated a “hold” rating on shares of Akorn in a research report on Tuesday, April 25th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have assigned a buy rating to the stock. Akorn presently has an average rating of “Hold” and an average price target of $30.55.
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.